Literature DB >> 1926345

Discodermolide--a new, marine-derived immunosuppressive compound. II. In vivo studies.

R E Longley1, D Caddigan, D Harmody, M Gunasekera, S P Gunasekera.   

Abstract

The in vivo immunosuppressive properties of a novel, marine-derived compound, discodermolide, are reported here. Discodermolide was effective in suppressing the graft-versus-host splenomegaly response of BALB/c----CB6F1 (BALB/c X C57BL/6J)F1 grafted mice at 5.0, 2.5, and 1.25 mg/kg, when administered as daily, i.p. injections, for 7 days. Mice treated with 5.0 and 2.5 mg/kg demonstrated a high degree of suppression (219 and 150%, respectively); however, these dosages were associated with some degree of morbidity (2/5 and 4/5 survivors for 5.0 and 2.5 mg/kg, respectively). Mice that were treated with 1.25, 0.625, and 0.313 mg/kg remained healthy after a 7-day regimen, and continued to demonstrate suppression of splenomegaly (106%, 72%, and 76% suppression, respectively). Splenocytes obtained from discodermolide-treated, allogeneic grafted mice were suppressed in their ability to respond in vitro to optimal mitogenic concentrations of concanavalin A, and natural-killer-cell activity directed against YAC-1 tumor cells, compared with vehicle-treated, allogeneic grafted control mice. Lower dosages (2.5 and 1.25 mg/kg) of discodermolide, however, did not affect the subsequent ability of splenocytes obtained from these mice to produce IL-2 following in vitro stimulation with Con A. This was observed to be in contrast to the immunosuppressive activity observed with cyclosporine treatment of mice (150 mg/kg) for the ex vivo suppression of splenocyte production of IL-2. Treatment of normal, nongrafted mice with similar high dosages of discodermolide (5.0 mg/kg) for 4 days did not affect the primary antibody response of mice immunized with sheep red blood cells as measured by hemagglutination activity of their serum. These results suggest that discodermolide's in vivo immunosuppressive action appears not to be that of a generalized immunosuppressive agent and that its specific in vivo mechanism of action warrants further preclinical evaluation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1926345     DOI: 10.1097/00007890-199110000-00015

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  11 in total

1.  (+)-Discodermolide: Total Synthesis, Construction of Novel Analogues, and Biological Evaluation.

Authors:  Amos B Smith; B Scott Freeze
Journal:  Tetrahedron       Date:  2007-01-07       Impact factor: 2.457

Review 2.  Drug development from marine natural products.

Authors:  Tadeusz F Molinski; Doralyn S Dalisay; Sarah L Lievens; Jonel P Saludes
Journal:  Nat Rev Drug Discov       Date:  2008-12-19       Impact factor: 84.694

Review 3.  Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.

Authors:  Carlo Ballatore; Kurt R Brunden; Donna M Huryn; John Q Trojanowski; Virginia M-Y Lee; Amos B Smith
Journal:  J Med Chem       Date:  2012-09-28       Impact factor: 7.446

Review 4.  Marine anticancer drugs and their relevant targets: a treasure from the ocean.

Authors:  Manisha Nigam; Hafiz Ansar Rasul Suleria; Mohammad Hosein Farzaei; Abhay Prakash Mishra
Journal:  Daru       Date:  2019-06-05       Impact factor: 3.117

5.  Design and synthesis of (+)-discodermolide-paclitaxel hybrids leading to enhanced biological activity.

Authors:  Amos B Smith; Keizo Sugasawa; Onur Atasoylu; Chia-Ping Huang Yang; Susan Band Horwitz
Journal:  J Med Chem       Date:  2011-08-26       Impact factor: 7.446

Review 6.  Utilization of Photoaffinity Labeling to Investigate Binding of Microtubule Stabilizing Agents to P-Glycoprotein and β-Tubulin.

Authors:  Chia-Ping Huang Yang; Susan Band Horwitz; Hayley M McDaid
Journal:  J Nat Prod       Date:  2022-03-03       Impact factor: 4.803

7.  Human liver microsomal metabolism of (+)-discodermolide.

Authors:  Yun Fan; Emanuel M Schreiber; Billy W Day
Journal:  J Nat Prod       Date:  2009-10       Impact factor: 4.050

8.  Distinct pose of discodermolide in taxol binding pocket drives a complementary mode of microtubule stabilization.

Authors:  Marina Khrapunovich-Baine; Vilas Menon; Pascal Verdier-Pinard; Amos B Smith; Ruth Hogue Angeletti; Andras Fiser; Susan Band Horwitz; Hui Xiao
Journal:  Biochemistry       Date:  2009-12-15       Impact factor: 3.162

9.  Insights into 4E-BP1 and p53 mediated regulation of accelerated cell senescence.

Authors:  Suzan K Chao; Susan Band Horwitz; Hayley M McDaid
Journal:  Oncotarget       Date:  2011 Jan-Feb

10.  Novel Marine Compounds: Anticancer or Genotoxic?

Authors:  Jamal M. Arif; Amal A. Al-Hazzani; Muhammed Kunhi; Fahad Al-Khodairy
Journal:  J Biomed Biotechnol       Date:  2004
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.